CA3168495A1 - Isoindoline derivatives which bind to an atp binding site - Google Patents
Isoindoline derivatives which bind to an atp binding siteInfo
- Publication number
- CA3168495A1 CA3168495A1 CA3168495A CA3168495A CA3168495A1 CA 3168495 A1 CA3168495 A1 CA 3168495A1 CA 3168495 A CA3168495 A CA 3168495A CA 3168495 A CA3168495 A CA 3168495A CA 3168495 A1 CA3168495 A1 CA 3168495A1
- Authority
- CA
- Canada
- Prior art keywords
- formula
- dihydroxy
- methyl
- piperazin
- isoindolin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6875—Nucleoproteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
- G01N2333/922—Ribonucleases (RNAses); Deoxyribonucleases (DNAses)
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plural Heterocyclic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2000789.4A GB202000789D0 (en) | 2020-01-20 | 2020-01-20 | Novel probe molecules |
| GB2000789.4 | 2020-01-20 | ||
| GBGB2003559.8A GB202003559D0 (en) | 2020-03-11 | 2020-03-11 | Novel probe molecules |
| GB2003559.8 | 2020-03-11 | ||
| PCT/GB2021/050122 WO2021148786A1 (en) | 2020-01-20 | 2021-01-20 | Isoindoline derivatives which bind to an atp binding site |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3168495A1 true CA3168495A1 (en) | 2021-07-29 |
Family
ID=74285509
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3168495A Pending CA3168495A1 (en) | 2020-01-20 | 2021-01-20 | Isoindoline derivatives which bind to an atp binding site |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12517130B2 (https=) |
| EP (1) | EP4093731A1 (https=) |
| JP (1) | JP7671308B2 (https=) |
| CN (1) | CN115397811B (https=) |
| AU (1) | AU2021211925A1 (https=) |
| CA (1) | CA3168495A1 (https=) |
| WO (1) | WO2021148786A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021211925A1 (en) | 2020-01-20 | 2022-08-25 | Neophore Limited | Isoindoline derivatives which bind to an ATP binding site |
| GB202008201D0 (en) | 2020-06-01 | 2020-07-15 | Neophore Ltd | Inhibitor compounds |
| GB202110373D0 (en) * | 2021-07-19 | 2021-09-01 | Neophore Ltd | Inhibitor compounds |
| GB202307924D0 (en) * | 2023-05-26 | 2023-07-12 | Neophore Ltd | Inhibitor compounds |
| CN117586174B (zh) * | 2024-01-19 | 2024-05-10 | 中国药科大学 | 用于诊断结直肠癌的近红外荧光探针及其制法和应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0202133D0 (sv) | 2002-07-08 | 2002-07-08 | Astrazeneca Ab | Novel compounds |
| JP2008540395A (ja) | 2005-05-03 | 2008-11-20 | ファイザー・インク | アミドレソルシノール化合物 |
| GB0620259D0 (en) * | 2006-10-12 | 2006-11-22 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| JP5410285B2 (ja) | 2006-10-12 | 2014-02-05 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
| JP5518478B2 (ja) | 2006-10-12 | 2014-06-11 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
| WO2009060835A1 (ja) | 2007-11-05 | 2009-05-14 | Kyoto University | 新規ユビキリン結合性小分子 |
| GB0806527D0 (en) | 2008-04-11 | 2008-05-14 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| KR102668696B1 (ko) | 2012-01-12 | 2024-05-29 | 예일 유니버시티 | E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법 |
| EP3738594A1 (en) * | 2013-09-10 | 2020-11-18 | Madrigal Pharmaceuticals, Inc. | Targeted therapeutics having an hsp90 ligand as binding moiety |
| GB201502020D0 (en) | 2015-02-06 | 2015-03-25 | Cancer Rec Tech Ltd | Autotaxin inhibitory compounds |
| US20210275630A1 (en) | 2016-04-18 | 2021-09-09 | Phoremost Limited | Inactivation of dna repair as an anticancer therapy |
| MA45670A (fr) | 2016-07-13 | 2019-05-22 | Vertex Pharma | Procédés, compositions et kits pour augmenter l'efficacité d'édition du génome |
| EP3568128B1 (en) | 2017-01-12 | 2022-07-06 | The University of Kansas | Hsp90b n-terminal isoform-selective inhibitors |
| WO2019014600A1 (en) | 2017-07-13 | 2019-01-17 | Plex Pharmaceuticals, Inc. | TREATMENT OF ASSOCIATION FOR THE TREATMENT OF CANCER |
| WO2019118830A1 (en) * | 2017-12-14 | 2019-06-20 | Tarveda Therapeutics, Inc. | Hsp90-targeting conjugates and formulations thereof |
| EP3773670A4 (en) | 2018-04-05 | 2022-03-09 | Tarveda Therapeutics, Inc. | Hsp90-targeting conjugates and formulations thereof |
| CA3099155A1 (en) | 2018-05-14 | 2019-11-21 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| US11026963B2 (en) | 2018-07-11 | 2021-06-08 | Rubedo Life Sciences, Inc. | Senolytic compositions and uses thereof |
| GB201819126D0 (en) | 2018-11-23 | 2019-01-09 | Cancer Research Tech Ltd | Inhibitor compounds |
| AU2021211925A1 (en) | 2020-01-20 | 2022-08-25 | Neophore Limited | Isoindoline derivatives which bind to an ATP binding site |
| GB202008201D0 (en) | 2020-06-01 | 2020-07-15 | Neophore Ltd | Inhibitor compounds |
| GB202110373D0 (en) | 2021-07-19 | 2021-09-01 | Neophore Ltd | Inhibitor compounds |
| GB202300881D0 (en) | 2023-01-20 | 2023-03-08 | Neophore Ltd | Inhibitor compounds |
-
2021
- 2021-01-20 AU AU2021211925A patent/AU2021211925A1/en active Pending
- 2021-01-20 WO PCT/GB2021/050122 patent/WO2021148786A1/en not_active Ceased
- 2021-01-20 EP EP21702065.0A patent/EP4093731A1/en active Pending
- 2021-01-20 CA CA3168495A patent/CA3168495A1/en active Pending
- 2021-01-20 JP JP2022569300A patent/JP7671308B2/ja active Active
- 2021-01-20 US US17/793,912 patent/US12517130B2/en active Active
- 2021-01-20 CN CN202180023267.0A patent/CN115397811B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021211925A1 (en) | 2022-08-25 |
| CN115397811A (zh) | 2022-11-25 |
| JP7671308B2 (ja) | 2025-05-01 |
| CN115397811B (zh) | 2025-05-23 |
| EP4093731A1 (en) | 2022-11-30 |
| JP2023511229A (ja) | 2023-03-16 |
| US12517130B2 (en) | 2026-01-06 |
| US20230061002A1 (en) | 2023-03-02 |
| WO2021148786A1 (en) | 2021-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN115397811B (zh) | 与atp结合位点结合的异吲哚啉衍生物 | |
| CA2574040C (en) | Iap binding compounds | |
| DK2423201T3 (en) | Luminescent macrocyclic lanthanide complexes | |
| JP5727937B2 (ja) | ベンゾアセピン誘導体の合成方法 | |
| De León-Rodríguez et al. | Highly regioselective N-trans symmetrical diprotection of cyclen | |
| CN103819486B (zh) | 标记血清糖原磷酸化酶浓度水平的光亲和标记探针分子、其制备方法及医药用途 | |
| EP1140856B1 (en) | Fluorescent dyes for solid phase and solution phase screening | |
| WO2007136921A2 (en) | Small molecule apoptosis promoters | |
| Van De Langemheen et al. | Polar hinges as functionalized conformational constraints in (bi) cyclic peptides | |
| WO2009121244A1 (en) | Fluorophore compounds | |
| JP7523166B2 (ja) | コロナウイルス３ｃｌプロテアーゼを標的とするｖｈｌリガンドに基づくｐｒｏｔａｃ、およびその調製方法と応用 | |
| Taldone et al. | Design, synthesis, and evaluation of small molecule Hsp90 probes | |
| Benediktsdottir et al. | Antibacterial sulfonimidamide-based oligopeptides as type I signal peptidase inhibitors: Synthesis and biological evaluation | |
| Jang et al. | Fluorescence sensing of dopamine | |
| Davies et al. | Asymmetric synthesis of 3, 4-anti-and 3, 4-syn-substituted aminopyrrolidines via lithium amide conjugate addition | |
| Clavé et al. | A universal and ready-to-use heterotrifunctional cross-linking reagent for facile synthetic access to sophisticated bioconjugates | |
| CA3253801A1 (en) | N6-ADENOSINE METHYL TRANSFERASE PROTAC AND METHODS FOR USE | |
| EP1923397B1 (en) | Fluorinated amino acids and peptides | |
| JP6670502B2 (ja) | 神経伝達物質受容体のリガンドスクリーニングシステムの開発 | |
| Wodtke et al. | Solution-phase synthesis of the fluorogenic TGase 2 acyl donor Z-Glu (HMC)-Gly-OH and its use for inhibitor and amine substrate characterisation | |
| Litwin | I. Synthesis and Evaluation of Biologically Active Small Molecules. II. Synthesis of Novel Caspase Inhibitors | |
| Huber et al. | Application of the concept of oxime library screening by mass spectrometry (MS) binding assays to pyrrolidine-3-carboxylic acid derivatives as potential inhibitors of γ-aminobutyric acid transporter 1 (GAT1) | |
| Mukhlif et al. | Design, Synthesis And Molecular Docking Of L-Prolinamide Containing Thiazolidine-4-One Ring System As (ACE Inhibitors) | |
| CN104447899B (zh) | 一种用于制备肾素-血管紧张素-醛固酮系统双重抑制剂的化合物的中间体 | |
| US6664410B1 (en) | Solid phase nitrile synthesis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20241218 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241218 Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W200 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST OR RESPONSE SUBMITTED ONLINE Effective date: 20241218 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250106 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250106 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250106 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250109 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250429 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250523 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260303 |